Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

@article{Cusi2016LongTermPT,
  title={Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.},
  author={Kenneth Cusi and Beverly Orsak and Fernando Bril and Romina Lomonaco and Joan Hecht and Carolina Ortiz-Lopez and Fermin O. Tio and J. Hardies and Celia Darland and Nicolas Musi and Amy Webb and Paola Portillo-Sanchez},
  journal={Annals of internal medicine},
  year={2016},
  volume={165 5},
  pages={305-15}
}
BACKGROUND The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. OBJECTIVE To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. DESIGN Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682). SETTING University… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 157 times over the past 90 days. VIEW TWEETS
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com